Beginning July 1, MassHealth will stop covering GLP-1 and other anti-obesity medications prescribed solely for weight loss, a policy change expected to affect at least 22,000 Massachusetts residents
THE SCIENCE BEHIND THE FUTURE Scientific Sources Frequently Asked Questions Find answers to common questions about EllieMD
The number of bariatric procedures is also down at Temple University Health System, but patients with complex conditions and more severe obesity are still coming to Temple for surgery, said David Stein, who is surgeon-in-chief at Temple University Hospital
People with specific medical conditions, people managing complex medication interactions, or people who require clinical monitoring of body composition (for example, individuals with sarcopenia, osteoporosis, or eating disorders) should work with their licensed healthcare provider - not a wellness tracking app - as their primary support system
The final analysis included only adults with obesity and without diabetes, and only GLP-1 receptor agonist prescriptions with FDA indications as anti-obesity medications
Many people experience sustained weight loss and even improvements in metabolic health